Eva Kimby group
The research group focus on lymphoid malignancies of B-celltype, mainly chronic lymphocytic leukemia (CLL), follikular lymphoma (FL) och mantelcellymphoma (MCL). These are diseases in which the tumour cells accumulate within the immunesystem in bone-marrow, lymphnodes and spleen, but also in the blood.
Tumour cells accumulate within the immunesystem in bone-marrow
The research group is very active in collaboration with the Nordic Lymphoma group (NLG) in clinical trials and translational research and has an extensive international network.
The research focus is:
- Prognostic biomarkers in relation to tumour cells and immune-cells in the micro-environment
- Molecular and cytogenetic aberrations in tumour cells from different compartments
- Therapeutic trials with monoclonal antibodies (with or without immunmodulating drugs as lenalidomide) and predictive markers for response.
Eva Kimby, Group Leader, MD, PhD, Professor
Eva Kimby is professor of hematology at Karolinska Institutet, Huddinge and Solna and senior consultant at the Center for Hematology, Karolinska University Hospital. She leads a research group on lymphoid malignancies of B-celltype with focus on translational research.
Eva Kimby is chair of the NLG s indolent group, Member of the Medical Advisory Board for Waldenströms macroglobulinemia and in the Advisory Board European Network Mantle cell lymphoma and vice president in ERIC (European Research Initiative for CLL).
|Ann Wallblom, BMA|
|Birgitta Stellan, BMA|
|Aleksandra Krstic, PhD, Post doc|
|Björn Wahlin, M.D., Ph.D, Post doc|
|Stefan Norin, M.D., Ph.D, Post doc|
|Sandra Lockmer, ST-läkare, (KLL & FL), PhD student|
|Stefanie Baumgartner, (MCL)), PhD student|
|Lina Nygren, läkare, ST-forskarblock (MCL), PhD student|
|Aleksandra Krstic, PhD, Postdoc|
In the CLL research, a close collaboration with Robert Månsson, post doc, researchassistent HERM, on B-cell differentiation.